RPG Life Sciences Limited — PPTs, 28-07-2026: Investor Presentation

RPG Life Sciences reported a robust Q1 FY27, with revenue climbing 15.8% to ₹195.7 Cr and profit after tax (PAT) up 17.0% to ₹30.8 Cr, achieving a 15.7% PAT margin. Domestic Formulations (DF) led sales, growing 14.8% and contributing 68.3% of total revenue. International Formulations (IF) saw a 7.7% increase, while the API segment grew a strong 35.6%, despite a fire incident.

The company recently entered the "Top 50 Pharma Company" list in June '26, moving up from Rank 62, and was recognized among the Top 5 Fastest Growing in the Indian Pharma Market. Its ICRA rating was reaffirmed at A+ stable.

Strategic priorities include scaling core brands like Naprosyn towards ₹100 Cr+ and building a stronger specialty and chronic portfolio through new product launches. RPG Life Sciences is also focused on expanding its global footprint, strengthening its API business, and exploring M&A opportunities. Future plans are backed by significant capex since FY22 to enhance plant capacities and a robust digital roadmap for operational efficiency.